Boston Scientific Company Insiders

BSX Stock  USD 68.62  0.68  1.00%   
Slightly above 90 percent of Boston Scientific's insiders are activelly selling. The analysis of insiders' sentiment of trading Boston Scientific Corp stock suggests that a very large number of insiders are panicking at this time. Boston Scientific employs about 48 K people. The company is managed by 43 executives with a total tenure of roughly 287 years, averaging almost 6.0 years of service per executive, having 1116.28 employees per reported executive.
Michael Mahoney  Chairman
Chairman of the Board, President, Chief Executive Officer
Peter Nicholas  Chairman
Co-Founder and Chairman of The Board

Boston Scientific's Insider Buying Vs Selling

10

 
Selling
 
Buying

Latest Trades

2024-03-01Wendy CarruthersDisposed 6983 @ 66.35View
2024-02-23Wendy CarruthersDisposed 6983 @ 66.89View
2024-02-20Daniel J BrennanDisposed 13662 @ 65.86View
2024-02-13Edward J LudwigDisposed 7000 @ 65.03View
2024-01-12Joseph Michael FitzgeraldDisposed 11660 @ 60View
2024-01-09Jeffrey B MirvissDisposed 15172 @ 59.25View
2024-01-04Jeffrey B MirvissDisposed 15000 @ 58.4View
2023-12-06Jeffrey B MirvissDisposed 353 @ 55.03View
2023-12-04John R. CurtisDisposed @ 54.77
2023-11-06Michael F MahoneyDisposed 113356 @ 52.51View
2023-10-16Wendy CarruthersDisposed 11671 @ 49.79View
2023-10-09Michael F MahoneyDisposed 113355 @ 52.09View
2023-10-03Markwayne MullinAcquired @ 51.54
2023-09-20Joseph Michael FitzgeraldDisposed 15867 @ 55View
2023-09-15Wendy CarruthersDisposed 11671 @ 53.95View
2023-09-13Markwayne MullinAcquired @ 53.21
2023-09-12Michael F MahoneyDisposed 113355 @ 53.91View
2023-09-08Lois FrankelDisposed @ 53.87
2023-08-28Jeffrey B MirvissDisposed 13971 @ 53.14View
2023-08-25Vance R BrownDisposed 15750 @ 50.52View
Monitoring Boston Scientific's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.

Acquired vs Disposed

Filed vs Not Filed

Insider sentiment refers to the collective sentiment or feeling of Boston Scientific's insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Boston Scientific Corp. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Boston Scientific's stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boston Scientific Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

Boston Scientific's Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Boston Scientific's future performance. Based on our forecasts, it is anticipated that Boston will maintain a workforce of slightly above 48000 employees by April 2024.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Boston Scientific's latest congressional trading

Congressional trading in companies like Boston Scientific Corp, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Boston Scientific by those in governmental positions are based on the same information available to the general public.
2023-12-04Representative John CurtisDisposed Under $15KVerify
2023-10-03Senator Markwayne MullinAcquired Under $15KVerify
2023-09-08Representative Lois FrankelDisposed Under $15KVerify
2022-10-24Representative Alan S. LowenthalDisposed Under $15KVerify
2021-12-16Representative Robert J. WittmanDisposed Under $15KVerify
2021-07-21Representative Kevin HernAcquired $15K to $50KVerify
2021-02-16Representative Peter MeijerAcquired Under $15KVerify
2020-12-18Representative Dean PhillipsDisposed Under $15KVerify
2020-11-27Representative Michael T. McCaulAcquired $15K to $50KVerify
2020-04-09Representative Josh GottheimerDisposed Under $15KVerify
2020-03-18Representative Gilbert CisnerosAcquired Under $15KVerify
2020-02-05Representative Mo BrooksDisposed Under $15KVerify
2019-04-25Representative Susie LeeDisposed Under $15KVerify

Boston Scientific Management Team Effectiveness

The company has Return on Asset of 0.0447 % which means that on every $100 spent on assets, it made $0.0447 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0858 %, implying that it generated $0.0858 on every 100 dollars invested. Boston Scientific's management efficiency ratios could be used to measure how well Boston Scientific manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Boston Scientific's Return On Capital Employed is fairly stable compared to the past year. Return On Assets is likely to rise to 0.05 in 2024, whereas Return On Equity is likely to drop 0.06 in 2024. At this time, Boston Scientific's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 30.1 B in 2024, whereas Total Current Assets are likely to drop slightly above 3.3 B in 2024.
Net Income Applicable To Common Shares is likely to rise to about 775.2 M in 2024, whereas Common Stock Shares Outstanding is likely to drop slightly above 1.2 B in 2024.

Boston Scientific Workforce Comparison

Boston Scientific Corp is rated third in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 183,593. Boston Scientific totals roughly 48,000 in number of employees claiming about 26% of equities under Health Care industry.

Boston Scientific Profit Margins

The company has Net Profit Margin of 0.11 %, which implies that it may need a different competitive strategy as even a very small decline in it revenue may erase profits and result in a net loss. This is way below average. In the same way, it shows Net Operating Margin of 0.17 %, which entails that for every 100 dollars of revenue, it generated $0.17 of operating income.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.770.6949
Significantly Up
Slightly volatile

Boston Scientific Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Boston Scientific insiders, such as employees or executives, is commonly permitted as long as it does not rely on Boston Scientific's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Boston Scientific insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-03-01
0.6544
89
136
 1,240,350 
 955,834 
2023-12-01
0.6522
15
23
 322,738 
 665,225 
2023-09-01
0.72
18
25
 288,396 
 681,116 
2023-06-01
1.0526
20
19
 147,730 
 309,339 
2023-03-01
0.6667
98
147
 1,112,604 
 747,843 
2022-12-01
0.2963
8
27
 364,560 
 1,165,278 
2022-09-01
0.3333
7
21
 257,508 
 1,101,738 
2022-06-01
1.5
15
10
 118,446 
 49,307 
2022-03-01
0.6726
152
226
 1,493,498 
 831,014 
2021-12-01
0.4286
9
21
 479,057 
 960,871 
2021-09-01
0.5897
23
39
 820,822 
 1,545,234 
2021-06-01
0.5
19
38
 158,837 
 545,389 
2021-03-01
0.7212
163
226
 1,885,897 
 1,020,519 
2020-12-01
0.3846
5
13
 60,688 
 374,903 
2020-09-01
0.2857
8
28
 303,856 
 485,019 
2020-06-01
1.1818
13
11
 53,348 
 30,129 
2020-03-01
0.6979
164
235
 2,079,256 
 1,191,108 
2019-12-01
0.4324
16
37
 246,045 
 511,738 
2019-09-01
0.3913
9
23
 119,097 
 224,036 
2019-06-01
0.75
21
28
 82,708 
 160,051 
2019-03-01
0.7018
153
218
 2,346,276 
 1,607,760 
2018-12-01
0.3871
12
31
 114,341 
 458,521 
2018-09-01
0.375
6
16
 95,942 
 320,077 
2018-06-01
0.6452
20
31
 182,138 
 383,514 
2018-03-01
0.7537
153
203
 2,605,910 
 1,716,307 
2017-12-01
0.5185
14
27
 761,728 
 831,881 
2017-09-01
0.6
18
30
 193,602 
 451,815 
2017-06-01
0.92
23
25
 178,279 
 282,317 
2017-03-01
0.8511
160
188
 3,149,899 
 1,755,618 
2016-12-01
0.5
9
18
 403,658 
 654,202 
2016-09-01
0.5625
9
16
 174,275 
 553,178 
2016-06-01
1.0
26
26
 332,058 
 1,005,299 
2016-03-01
0.8144
158
194
 3,841,811 
 2,398,433 
2015-12-01
0.4783
11
23
 407,999 
 822,833 
2015-09-01
2.75
11
4
 540,849 
 55,137 
2015-06-01
1.5
24
16
 310,456 
 443,462 
2015-03-01
0.77
154
200
 3,785,178 
 2,542,222 
2014-12-01
1.5
15
10
 507,186 
 581,716 
2014-09-01
0.4118
7
17
 108,431 
 235,186 
2014-06-01
0.5833
7
12
 42,823 
 111,000 
2014-03-01
0.8743
146
167
 2,959,471 
 1,221,529 
2013-12-01
0.5
17
34
 946,371 
 2,106,860 
2013-09-01
0.4706
8
17
 517,873 
 1,101,745 
2013-06-01
1.0769
14
13
 274,607 
 110,178 
2013-03-01
0.7688
123
160
 3,808,593 
 950,470 
2012-12-01
2.3333
14
6
 398,832 
 459,392 
2012-09-01
0.1613
10
62
 90,749 
 11,891,140 
2012-06-01
0.1667
17
102
 362,273 
 20,744,265 
2012-03-01
0.812
108
133
 3,604,301 
 4,248,999 
2011-12-01
1.0769
14
13
 2,472,556 
 517,439 
2011-09-01
0.4242
14
33
 157,956 
 230,787 
2011-06-01
1.6923
22
13
 479,885 
 191,644 
2011-03-01
0.9487
74
78
 3,349,957 
 298,759 
2010-12-01
0.0734
8
109
 535,188 
 5,903,796 
2010-09-01
0.2557
45
176
 6,551,121 
 7,080,122 
2010-06-01
0.4084
78
191
 10,982,254 
 6,661,521 
2010-03-01
0.6447
98
152
 7,098,631 
 5,894,169 
2009-12-01
0.4386
50
114
 2,794,959 
 9,860,765 
2009-09-01
0.7451
38
51
 1,736,587 
 3,418,231 
2009-06-01
0.661
39
59
 1,055,657 
 4,356,189 
2009-03-01
0.5865
78
133
 6,491,988 
 10,942,940 
2008-12-01
0.3716
55
148
 4,118,934 
 61,475,535 
2008-09-01
0.9167
33
36
 1,574,081 
 335,261 
2008-06-01
1.56
39
25
 1,590,011 
 1,176,869 
2008-03-01
7.2857
51
7
 4,200,753 
 181,999 
2007-12-01
0.5789
11
19
 168,165 
 367,270 
2007-09-01
0.7143
25
35
 267,521 
 28,355,192 
2007-06-01
0.1413
38
269
 5,398,243 
 24,845,411 
2007-03-01
10.0
10
1
 149,350 
 11,200 
2006-12-01
5.6667
17
3
 699,848 
 15,700,950 
2006-09-01
12.5
25
2
 552,288 
 16,127,050 
2006-06-01
3.6667
44
12
 1,061,920 
 493,031 
2006-03-01
3.1
31
10
 2,524,053 
 47,069 
2005-12-01
1.4
7
5
 9,758 
 13,198 
2005-09-01
8.25
33
4
 1,954,192 
 52,000 
2005-06-01
0.7544
43
57
 1,119,693 
 1,495,058 
2005-03-01
1.3158
25
19
 1,472,940 
 213,586 
2004-12-01
0.4333
13
30
 366,706 
 446,334 
2004-09-01
1.1765
20
17
 204,019 
 256,666 
2004-06-01
0.2673
54
202
 2,053,373 
 4,987,067 
2004-03-01
0.3103
36
116
 1,984,939 
 4,300,416 
2003-12-01
0.1103
46
417
 2,364,200 
 2,961,368 
2003-09-01
0.0181
11
607
 1,077,898 
 1,926,960 
2003-06-01
5.0
5
1
 1,078 
 27,000 

Boston Scientific Notable Stakeholders

A Boston Scientific stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Boston Scientific often face trade-offs trying to please all of them. Boston Scientific's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Boston Scientific's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Michael MahoneyChairman of the Board, President, Chief Executive OfficerProfile
Peter NicholasCo-Founder and Chairman of The BoardProfile
Kevin BallingerExecutive Vice President and Global President - Interventional CardiologyProfile
Desiree RallsMorrisonSenior Vice President General Counsel, Corporate SecretaryProfile
Keith DawkinsGlobal Chief Medical Officer, Executive Vice PresidentProfile
Maulik NanavatySenior Vice President and President - NeuromodulationProfile
Ian MeredithExecutive Vice President Global Chief Medical OfficerProfile
David PierceExecutive Vice President and President, MedSurg and President - EndoscopyProfile
Supratim BoseExecutive VP and President of Asia-Pac, Middle East and AfricaProfile
Joseph FitzgeraldExecutive Vice President, President, Interventional CardiologyProfile
Warren WangSenior Vice President and President - Asia PacificProfile
Eric ThepautExecutive Vice President and President - Europe, Middle East and AfricaProfile
Wendy CarruthersExecutive Vice President - Human ResourcesProfile
Jodi EddySenior Vice President and Chief Information and Digital OfficerProfile
John SorensonSenior Vice President - Manufacturing and Supply ChainProfile
Arthur ButcherExecutive Vice President and President, Asia PacificProfile
Edward MackeyExecutive Vice President - Global OperationsProfile
Karen PrangeSenior Vice President and President - Urology & Women's HealthProfile
Scott OlsonSenior Vice President, President - Cardiac Rhythm Management and DiagnosticsProfile
Michael PhalenExecutive Vice President and President - MedSurgProfile
Jeffrey MirvissExecutive Vice President and President - Peripheral InterventionsProfile
Jonathan MonsonChief Accounting Officer, Vice President Global ControllerProfile
Meghan ScanlonSenior Vice President and President - Urology and Pelvic HealthProfile
Daniel BrennanCFO, Principal Accounting Officer and Executive VPProfile
Timothy PrattChief Admin. Officer, Executive VP, General Counsel and SecretaryProfile
Edward LudwigLead Independent DirectorProfile
Donna JamesIndependent DirectorProfile
Stephen MacMillanIndependent DirectorProfile
Ellen ZaneIndependent DirectorProfile
Kristina JohnsonIndependent DirectorProfile
Nelda ConnorsIndependent DirectorProfile
Ernest MarioIndependent DirectorProfile
N NicholasIndependent DirectorProfile
Charles DockendorffIndependent DirectorProfile
John SununuIndependent DirectorProfile
Yoshiaki FujimoriIndependent DirectorProfile
David WichmannIndependent DirectorProfile
David RouxIndependent DirectorProfile
Emily WoodworthGlobal VPProfile
Susan LisaVP, Investor RelationsProfile
Catherine JenningsVP InterventionsProfile
Vance BrownSenior Vice President General Counsel, Corporate SecretaryProfile
Mary MoynihanSenior OfficerProfile

About Boston Scientific Management Performance

The success or failure of an entity such as Boston Scientific Corp often depends on how effective the management is. Boston Scientific management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Boston management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Boston management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for 2024
Return On Capital Employed 0.08  0.14 
Return On Assets 0.05  0.05 
Return On Equity 0.08  0.06 
The data published in Boston Scientific's official financial statements usually reflect Boston Scientific's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Boston Scientific Corp. For example, before you start analyzing numbers published by Boston accountants, it's critical to develop an understanding of what Boston Scientific's liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of Boston Scientific's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Boston Scientific's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Boston Scientific's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Boston Scientific Corp. Please utilize our Beneish M Score to check the likelihood of Boston Scientific's management manipulating its earnings.

Boston Scientific Workforce Analysis

Traditionally, organizations such as Boston Scientific use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Boston Scientific within its industry.

Boston Scientific Manpower Efficiency

Return on Boston Scientific Manpower

Revenue Per Employee296.7K
Revenue Per Executive331.2M
Net Income Per Employee33.2K
Net Income Per Executive37M
Working Capital Per Employee32.9K
Working Capital Per Executive36.8M
When determining whether Boston Scientific Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Boston Scientific's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Boston Scientific Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Boston Scientific Corp Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boston Scientific Corp. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Boston Stock analysis

When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Money Managers
Screen money managers from public funds and ETFs managed around the world
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Is Boston Scientific's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Boston Scientific. If investors know Boston will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Boston Scientific listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
2.856
Earnings Share
1.07
Revenue Per Share
9.8
Quarterly Revenue Growth
0.149
Return On Assets
0.0447
The market value of Boston Scientific Corp is measured differently than its book value, which is the value of Boston that is recorded on the company's balance sheet. Investors also form their own opinion of Boston Scientific's value that differs from its market value or its book value, called intrinsic value, which is Boston Scientific's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Boston Scientific's market value can be influenced by many factors that don't directly affect Boston Scientific's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Boston Scientific's value and its price as these two are different measures arrived at by different means. Investors typically determine if Boston Scientific is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Boston Scientific's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.